Tigermed 2026 Interim Results
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Aug 28, 2026
The strong interim results, with revenue and profit growth, are likely to positively impact Tigermed's stock price and investor sentiment. The strategic partnerships and acquisitions signal expansion and capability enhancement, potentially strengthening its competitive position in the CRO market.
Hangzhou Tigermed Consulting Co., Ltd., a leading global CRO, announced its 2026 interim results on August 28, 2026. Revenue grew 14.1% YoY to RMB 3,707.6 million, with adjusted net profit up 31.8% to RMB 277.7 million. The company signed strategic cooperation agreements with Hisun Pharmaceutical, Insilico Medicine, 3SBio, and a European multinational, completed acquisitions of Teddy Laboratory and Shanghai Bioquick, and opened its new global headquarters in Hangzhou. Tigermed expanded its global footprint, establishing a subsidiary in New Zealand and commencing operations at a CDMO facility in the U.S. The company also advanced AI integration in clinical research, developing an intelligent platform and SAP system. Management expressed optimism about the recovering biopharmaceutical industry and continued globalization of China's innovative medicines.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard